Women's Health

The patient’s symptoms gradually resolved after discontinuing fezolinetant therapy.

A conversation with Julia L. Ziegengeist, PharmD, BCOP, clinical pharmacist coordinator of breast medical oncology for the Levine Cancer Institute at Atrium Health.

A conversation with Kathleen Vest, PharmD, BCACP, CDCES, FCCP, professor of Pharmacy Practice at Drake University College of Pharmacy and Health Sciences.

Women with prepregnancy overweight or obesity may be more likely to experience postpartum depression.

Despite an interest in services, a majority of women do not have these critical conversations with their health care providers.

Systemic lupus erythematosus is associated with a higher risk of cervical dysplasia due to the inflammatory nature of the disease.

Premenstrual Dysphoric Disorder is considered a psychiatric disorder and is associated with moderate to severe physical, affective, and behavioral symptoms.

Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.

As “therapeutic orphans,” pregnant women and their health care providers must balance the benefits of treatment with the risk of fetal harm.

GoodRx’s new e-commerce service further expands access to Opill by allowing consumers to order the birth control directly to their homes without a prescription.

Women experiencing later menopause may face a heightened risk of asthma, underscoring the possible role of estrogen in the development of the condition.

With nearly 7 million women living in a health care desert, pharmacists can provide crucial reproductive care services.

The FDA has approved just the second treatment for uncomplicated urinary tract infections (UTIs) in the last 2 decades.

The cost effectiveness of biosimilar denosumab for postmenopausal osteoporosis varies significantly based on factors like adherence, subsequent therapies, and treatment duration.

A series of posters presented at AMCP Nexus 2024 highlighted the evolving landscape of women's health, focusing on the use of medications for preterm birth prevention and the adoption of telehealth for prenatal consultations.

Posters presented at IDWeek 2024 provided new insights into the impact of COVID-19 infection and vaccination on women’s health.

Three posters showcased at IDWeek 2024 focused on enhancing access to HIV prevention and treatment, as well as increasing uptake of pre-exposure prophylaxis (PrEP) among women.

Vaccination against HPV can prevent thousands of cases of cancer each year.

Gepotidacin is a first-in-class oral antibiotic with a novel mechanism of action.

The financial burden of in vitro fertilization (IVF) medications has become increasingly prohibitive, limiting the availability of fertility treatments for many.

Research from ESMO 2024 focused on the relationship between survival outcomes and medication adherence.

The therapy’s Prescription Drug User Fee Act date has been set for July 26, 2025.

Stephanie Sober, MD, MSHP, shares insights into the research that led to Opill’s FDA approval and its implications for women’s access to contraception.

This approval offers an additional treatment option for a disease that can commonly return.

Stephanie Sober, MD, MSHP, investigator on the pivotal research that supported the prescription-to-OTC switch of Opill, shares insights on how the medicine is reshaping the reproductive landscape.